Detailed Study of the Non-Small Cell Lung Cancer - Pipeline Review, H1 2016

Non-Small Cell Lung Cancer - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Non-Small Cell Lung Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

To view the table of contents and know more details please visit Non-Small Cell Lung Cancer - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
- The report reviews pipeline therapeutics for Non-Small Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

3-V Biosciences, Inc. 4SC AG AbbVie Inc. Ability Pharmaceuticals, S.L. ACEA Biosciences, Inc. Acetylon Pharmaceuticals, Inc. Adaptimmune Therapeutics Plc Advanced Cancer Therapeutics Advenchen Laboratories, LLC Aeolus Pharmaceuticals, Inc. Altimmune, Inc. Altor BioScience Corporation Amgen Inc. Andarix Pharmaceuticals, Inc. AndroScience Corporation Apac Biotech Pvt Ltd APO-T B.V. Aptose Biosciences Inc. Argos Therapeutics, Inc. Ariad Pharmaceuticals, Inc. Arog Pharmaceuticals, Inc. ArQule, Inc. Array BioPharma Inc. Arrien Pharmaceuticals, LLC Astellas Pharma Inc. Asterias Biotherapeutics, Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc ATLAB Pharma SAS Aurigene Discovery Technologies Limited AVEO Pharmaceuticals, Inc. Azaya Therapeutics, Inc. Basilea Pharmaceutica AG Batu Biologics, Inc. Bavarian Nordic A/S Bayer AG BeiGene, Ltd. Benitec Biopharma Limited BerGenBio AS Beta Pharma, Inc. Betta Pharmaceuticals Co. Ltd. BIND Therapeutics, Inc. Bio-Path Holdings, Inc. etc,.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###